HIV transmitted drug resistance results obtained by population survey methods are location and site specific and it may not be representative of the entire state or nation. weight of 16 was 261 copies/ml. Of the 38 samples tested, 34 (89%) were successfully genotyped. The SDRM rate was <5% for those ART drug classes, with 1/34 (2.9%) for NRTIs/NNRTIs and none for protease inhibitors 0/31 (0%). The specific SDRMs recognized were M41L for nucleoside reverse transcriptase inhibitors (NRTIs) and G190A for nonnucleoside reverse transcriptase inhibitors (NNRTIs). HIV-1 subtypes recognized were CRF02_AG (38.2%), G (41.2%), PF-04447943 G (14.7%), CRF06-CPX (2.9%), and a unique AG recombinant form (2.9%). The solitary ARV-native pregnant female with SDRMs was infected with HIV-1 subtype G. Access to ART has been available in the Jos area for over 8 years. The prevalence of TDR lower than 5% suggests appropriate ART administration, although continued surveillance is definitely warranted. == Intro == Effective use of antiretroviral drugsfor therapy (ART) markedly reduces the morbidity and mortality associated with HIV illness.1,2In addition, the appropriate use of a combination of antiretroviral drugs (ARVs) in both breastfeeding and nonbreastfeeding populations offers resulted in reductions of mother-to-child transmission rates from 15% to 45% to less than 2%.35However, the rapid scale-up of ART in resource-limited countries is not without its difficulties including inadequate capacity for treatment monitoring, limited options of ARV drug options for those failing therapy, intermittent interruptions in drug supply, treatment adherence problems, and emerging HIV genetic diversity.68These are factors that could gas the emergence of HIV drug resistance. It is feared that HIV-infected individuals may transmit drug-resistant viruses to others in the society and babies may acquire resistant disease from their infected mothers at birth and PF-04447943 during breastfeeding.9,10The periodic surveillance of the prevalence, pattern, and trends of HIV transmitted drug resistance and the identification of circulating subtypes are therefore recommended so that timely interventions can be implemented as needed.11This practice will help in ensuring that the efficacy of antiretroviral drugs utilized for ART, prevention of mother-to-child transmission (PMTCT), treatment for prevention, and preexposure and postexposure prophylaxis are preserved. The population of Nigeria is about 162 million people, with an estimated 3.3 million people living with HIV/AIDS.12The quantity of HIV/AIDS-related deaths in the country is estimated at 217,000.2,12In Jos, Nigeria, the site of this study, only a small number of HIV-infected DHRS12 patients could afford to purchase ARV drugs in the late 1990s. In 2002, the federal government rolled-out ART to 10,000 adult individuals and 5,000 HIV-positive children in 25 tertiary Health Organizations in the six geopolitical regions of the country and subsequent development of ART services offers continued to day with support from your President’s Emergency Plan For AIDS Alleviation (PEPFAR), Global Account, and other international funders, thus increasing the essential mass of HIV-infected individuals receiving ARVs to about 400,000; yet, an estimated 1.5 million eligible patients are still in need.12Jos University Teaching Hospital (JUTH) located PF-04447943 in Plateau state was one of the federal hospitals designated to provide ART. Plateau state has a human population of 3.2 million and to date it is estimated that over 20,000 HIV-positive individuals PF-04447943 have been enrolled on ART in government, faith-based, and private health organizations.12The use of single dose nevirapine (sdNVP) intervention for PMTCT in labor for mother and infants, which is known to be associated with the rapid emergence of drug resistance, also started in Nigeria within the same period of ART scale-up.9,12,13Compared to other countries with high burdens of HIV, studies reporting HIV genotypes and drug resistance in Nigeria are few and there is a dearth of information with this challenging part of HIV infection control.1416Studies that have surveyed drug resistance among antiretroviral-naive individuals in Nigeria have reported low rates of <5%.14,16,17This is comparable to similar reports from other sub-Sahara African countries.1820However, a recent statement from Kampala, Uganda described a dramatic increase from 0% to 8.6% in transmitted drug resistance within 10 years of the introduction of ART.21This finding further justifies the need for vigilance in areas where ART has been rolled out. WHO has recommended a simple and cost-effective protocol for determining the prevalence of TDR in resource-limited settings.11,22This employs the use of a binomial sequential sampling technique to obtain 3447 samples for genotyping from ARV-naive primigravid women less than 25 years old who are newly recognized as HIV infected at antenatal enrollment or.